The Shop VisiVite Blog

    Does your Eye Vitamin have what's on the label?

    VisiVite regularly tests its competitors’ products, and the results are often not pretty. This is especially true of the carotenoids, lutein and zeaxanthin.
    Read the article

    Glaucoma - The Sneak Thief of Sight

    Imagine an eye disease that causes no symptoms, permits people to have 20/20 vision, and has nothing to do with whether you wear eyeglasses or not. And it can make you go blind.
    Read the article

    Crying in the Eye Doctor's Office

    Some days, working as a Technical Coordinator for a high level Ophthalmologist in the New York area can be quite emotional. The word "Tears" comes up quite frequently in my daily routine. "My eyes tear too much" "My eyes feel dry, like I have no...
    Read the article

    Ultimate insiders Guide to Eye Health


    Get this ebook now

    Subscribe to our newsletter
    VisiVite needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at anytime.

    Recent Articles

    More like this

    FDA approves new treatment for wet AMD

    The Food and Drug Administration announced yesterday the approval of Vabysmo to treat both neovascular age-related macular degeneration (nAMD) as well as diabetic macular edema (DME). The new drug has the ability to target two pathways involved in [...]

    Lawsuit filed against Regeneron over price gouging with Eylea

    Blue Cross and Blue Shield of Massachusetts (BCBSMA) filed a lawsuite in federal court alleging that Regeneron Pharmaceuticals illegally inflated the price of Eylea. Eylea is used to treat wet age-related macular degeneration and cost $1,850 per [...]

    New wet AMD treatment shows promise in phase 3 study

    A new therapy for the treatment of wet age-related macular degeneration is showing good safety and efficacy after completing the phase 3 study. Researchers compared the new drug, ONS-5030 (bevacizumab - vikg) against ranibizumab in a 12 month NORSE [...]

    FDA approves new anti-vitreal therapy for wet AMD

    The FDA recently announced its approval of BYOOVIZ™ as a treatment for wet age-related macular degeneration making the drug the first ophthalmology biosimilar to gain FDA approval in the United States. Biosimilar drugs are very close in structure [...]

    Researchers find possible new cause of age-related macular degeneration

    Researchers at the University of Maryland School of Medicine have identified another possible causal factor in the development of age-related macular degeneration.

    Epimacular Brachytherapy Not Beneficial in Treating Wet Macular Degeneration

    Wet macular-degeneration is the leading cause of blindness in Europe and North America and anti-VEGF injections are the main therapies used to treat the disease. Epimacular Brachytherpay (EMB) was developed as a possible alternative treatment for [...]

    Macular Degeneration Anti-VEGF Injections do not raise risk of stroke or death

    A recent study concluded that anti-VEGF therapy for treating age-related macular degeneration (AMD) does not increase the risk of stroke, myocardial infarction or death. The retrospective study results were published in the online edition of JAMA [...]
    More recent articles
    View all articles
    WANT SOMETHING AMAZING?

    Ultimate insiders Guide to Eye Health

    Newly updated popular book by Dr. Paul Krawitz - now available as a FREE DOWNLOAD. Includes AREDS2 study results and explanations, the 'Ultimate Insider's Guide to Eye Health" contains critical information about common eye problems, including macular degeneration, dry eye syndrome, cataract surgery, diabetic retinopathy, and contact lenses.

    Get this ebook now